Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL405139 | 0.71 | DRD2 (0.48) | HTR2AHTR2C | |
| SCHEMBL23719718 | 0.68 | ALDH1A1 (0.36) | NOS3NOS1NOS2HTR2AHTR2C | |
| SCHEMBL406231 | 0.67 | DRD2 (0.47) | HTR2AHTR2C | |
| SCHEMBL23746915 | 0.65 | ALDH1A1 (0.33) | HTR2AHTR2CROCK1 | |
| SCHEMBL401463 | 0.59 | DRD2 (0.50) | — | |
| SCHEMBL23107125 | 0.58 | CCR1 (0.35) | NOS3NOS2 | |
| SCHEMBL31627421 | 0.57 | GABRA1 (0.42) | SIGMAR1 | |
| SCHEMBL1395813 | 0.56 | MCL1 (0.44) | HTR2AHTR2C | |
| SCHEMBL30955312 | 0.56 | MCL1 (0.44) | HTR2AHTR2C | |
| SCHEMBL31401032 | 0.55 | NOS3 (0.47) | NOS3NOS1NOS2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-08-12 | — | — | US | disclosed |
| WO-2021155196-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | PFIZER INC. | 2008-12-18 | — | — | US | disclosed |
| WO-2008012622-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246140-A1 | MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 | GRM1, GRM2, GRIN1 | NOS3 3621/4885NOS1 3091/4885NOS2 2729/4885 |
| US-20080312271-A1 | AZABENZIMIDAZOLYL COMPOUNDS | AZI2, PAICS, UGT2B7 | NOS3 2568/4885NOS1 3411/4885NOS2 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.